APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Radiopharmaceuticals for Therapeutic

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Radiopharmaceuticals for Therapeutic Market Outlook and Growth Opportunities 2026

Report ID 17403067042 January 2026197 pages

Choose your research edition.

Industry ResearchRadiopharmaceuticals for Therapeutic Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Radiopharmaceuticals for Therapeutic Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal Radiopharmaceuticals for Therapeutic Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Radiopharmaceuticals for Therapeutic Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Radiopharmaceuticals for Therapeutic Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Radiopharmaceuticals for Therapeutic market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Radiopharmaceuticals for Therapeutic is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Radiopharmaceuticals for Therapeutic is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Radiopharmaceuticals for Therapeutic is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Radiopharmaceuticals for Therapeutic market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Radiopharmaceuticals for Therapeutic market include Novartis, Bayer, Q BioMed, Mundipharma, Lantheus, Jubilant Radiopharma, International Isotopes, Dongcheng and Curium Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Radiopharmaceuticals for Therapeutic market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Radiopharmaceuticals for Therapeutic and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Radiopharmaceuticals for Therapeutic revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Radiopharmaceuticals for Therapeutic market.

Radiopharmaceuticals for Therapeutic Segment by Company

Novartis

Bayer

Q BioMed

Mundipharma

Lantheus

Jubilant Radiopharma

International Isotopes

Dongcheng

Curium Pharmaceuticals

China Isotope & Radiation

Aurobindo Pharma

Radiopharmaceuticals for Therapeutic Segment by Type

Radium-223

Lutetium-177

Iodine-131

Other

Radiopharmaceuticals for Therapeutic Segment by Application

Lymphoma

Thyroid

Bone Metastasis

Other

Radiopharmaceuticals for Therapeutic Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Radiopharmaceuticals for Therapeutic status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Radiopharmaceuticals for Therapeutic key companies, revenue, market share, and recent developments.

3. To split the Radiopharmaceuticals for Therapeutic breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Radiopharmaceuticals for Therapeutic market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Radiopharmaceuticals for Therapeutic significant trends, drivers, influence factors in global and regions.

6. To analyze Radiopharmaceuticals for Therapeutic competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Radiopharmaceuticals for Therapeutic market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Radiopharmaceuticals for Therapeutic and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Radiopharmaceuticals for Therapeutic.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Radiopharmaceuticals for Therapeutic industry.

Chapter 3: Detailed analysis of Radiopharmaceuticals for Therapeutic company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Radiopharmaceuticals for Therapeutic in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Radiopharmaceuticals for Therapeutic in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Radiopharmaceuticals for Therapeutic Industry Trends Table 2. Radiopharmaceuticals for Therapeutic Industry Drivers Table 3. Radiopharmaceuticals for Therapeutic Industry Opportunities and Challenges Table 4. Radiopharmaceuticals for Therapeutic Industry Restraints Table 5. Global Radiopharmaceuticals for Therapeutic Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Radiopharmaceuticals for Therapeutic Revenue Share by Company (2021-2026) Table 7. Global Radiopharmaceuticals for Therapeutic Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Radiopharmaceuticals for Therapeutic Key Company Manufacturing Base & Headquarters Table 9. Global Radiopharmaceuticals for Therapeutic Company, Product Type & Application Table 10. Global Radiopharmaceuticals for Therapeutic Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Radiopharmaceuticals for Therapeutic by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Radium-223 Table 15. Significant Companies of Lutetium-177 Table 16. Significant Companies of Iodine-131 Table 17. Significant Companies of Other Table 18. Global Radiopharmaceuticals for Therapeutic Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 19. Global Radiopharmaceuticals for Therapeutic Sales Value by Type (2021-2026) & (US$ Million) Table 20. Global Radiopharmaceuticals for Therapeutic Sales Value by Type (2027-2032) & (US$ Million) Table 21. Global Radiopharmaceuticals for Therapeutic Sales Value Share by Type (2021-2026) Table 22. Global Radiopharmaceuticals for Therapeutic Sales Value Share by Type (2027-2032) Table 23. Significant Companies of Lymphoma Table 24. Significant Companies of Thyroid Table 25. Significant Companies of Bone Metastasis Table 26. Significant Companies of Other Table 27. Global Radiopharmaceuticals for Therapeutic Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Radiopharmaceuticals for Therapeutic Sales Value by Application (2021-2026) & (US$ Million) Table 29. Global Radiopharmaceuticals for Therapeutic Sales Value by Application (2027-2032) & (US$ Million) Table 30. Global Radiopharmaceuticals for Therapeutic Sales Value Share by Application (2021-2026) Table 31. Global Radiopharmaceuticals for Therapeutic Sales Value Share by Application (2027-2032) Table 32. Global Radiopharmaceuticals for Therapeutic Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Radiopharmaceuticals for Therapeutic Sales Value by Region (2021-2026) & (US$ Million) Table 34. Global Radiopharmaceuticals for Therapeutic Sales Value Share by Region (2021-2026) Table 35. Global Radiopharmaceuticals for Therapeutic Sales Value by Region (2027-2032) & (US$ Million) Table 36. Global Radiopharmaceuticals for Therapeutic Sales Value Share by Region (2027-2032) Table 37. Global Radiopharmaceuticals for Therapeutic Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Radiopharmaceuticals for Therapeutic Sales Value by Country (2021-2026) & (US$ Million) Table 39. Global Radiopharmaceuticals for Therapeutic Sales Value Market Share by Country (2021-2026) Table 40. Global Radiopharmaceuticals for Therapeutic Sales Value by Country (2027-2032) & (US$ Million) Table 41. Global Radiopharmaceuticals for Therapeutic Sales Value Market Share by Country (2027-2032) Table 42. Novartis Company Information Table 43. Novartis Business Overview Table 44. Novartis Radiopharmaceuticals for Therapeutic Revenue (US$ Million) and Gross Margin (2021-2026) Table 45. Novartis Radiopharmaceuticals for Therapeutic Product Portfolio Table 46. Novartis Recent Development Table 47. Bayer Company Information Table 48. Bayer Business Overview Table 49. Bayer Radiopharmaceuticals for Therapeutic Revenue (US$ Million) and Gross Margin (2021-2026) Table 50. Bayer Radiopharmaceuticals for Therapeutic Product Portfolio Table 51. Bayer Recent Development Table 52. Q BioMed Company Information Table 53. Q BioMed Business Overview Table 54. Q BioMed Radiopharmaceuticals for Therapeutic Revenue (US$ Million) and Gross Margin (2021-2026) Table 55. Q BioMed Radiopharmaceuticals for Therapeutic Product Portfolio Table 56. Q BioMed Recent Development Table 57. Mundipharma Company Information Table 58. Mundipharma Business Overview Table 59. Mundipharma Radiopharmaceuticals for Therapeutic Revenue (US$ Million) and Gross Margin (2021-2026) Table 60. Mundipharma Radiopharmaceuticals for Therapeutic Product Portfolio Table 61. Mundipharma Recent Development Table 62. Lantheus Company Information Table 63. Lantheus Business Overview Table 64. Lantheus Radiopharmaceuticals for Therapeutic Revenue (US$ Million) and Gross Margin (2021-2026) Table 65. Lantheus Radiopharmaceuticals for Therapeutic Product Portfolio Table 66. Lantheus Recent Development Table 67. Jubilant Radiopharma Company Information Table 68. Jubilant Radiopharma Business Overview Table 69. Jubilant Radiopharma Radiopharmaceuticals for Therapeutic Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Jubilant Radiopharma Radiopharmaceuticals for Therapeutic Product Portfolio Table 71. Jubilant Radiopharma Recent Development Table 72. International Isotopes Company Information Table 73. International Isotopes Business Overview Table 74. International Isotopes Radiopharmaceuticals for Therapeutic Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. International Isotopes Radiopharmaceuticals for Therapeutic Product Portfolio Table 76. International Isotopes Recent Development Table 77. Dongcheng Company Information Table 78. Dongcheng Business Overview Table 79. Dongcheng Radiopharmaceuticals for Therapeutic Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. Dongcheng Radiopharmaceuticals for Therapeutic Product Portfolio Table 81. Dongcheng Recent Development Table 82. Curium Pharmaceuticals Company Information Table 83. Curium Pharmaceuticals Business Overview Table 84. Curium Pharmaceuticals Radiopharmaceuticals for Therapeutic Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. Curium Pharmaceuticals Radiopharmaceuticals for Therapeutic Product Portfolio Table 86. Curium Pharmaceuticals Recent Development Table 87. China Isotope & Radiation Company Information Table 88. China Isotope & Radiation Business Overview Table 89. China Isotope & Radiation Radiopharmaceuticals for Therapeutic Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. China Isotope & Radiation Radiopharmaceuticals for Therapeutic Product Portfolio Table 91. China Isotope & Radiation Recent Development Table 92. Aurobindo Pharma Company Information Table 93. Aurobindo Pharma Business Overview Table 94. Aurobindo Pharma Radiopharmaceuticals for Therapeutic Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. Aurobindo Pharma Radiopharmaceuticals for Therapeutic Product Portfolio Table 96. Aurobindo Pharma Recent Development Table 97. Research Programs/Design for This Report Table 98. Authors List of This Report Table 99. Secondary Sources Table 100. Primary Sources List of Figures Figure 1. Radiopharmaceuticals for Therapeutic Product Image Figure 2. Global Radiopharmaceuticals for Therapeutic Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Radiopharmaceuticals for Therapeutic Market Size (2021-2032) & (US$ Million) Figure 4. Global Radiopharmaceuticals for Therapeutic Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Radium-223 Image Figure 8. Lutetium-177 Image Figure 9. Iodine-131 Image Figure 10. Other Image Figure 11. Global Radiopharmaceuticals for Therapeutic Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 12. Global Radiopharmaceuticals for Therapeutic Sales Value Share 2021 VS 2025 VS 2032 Figure 13. Global Radiopharmaceuticals for Therapeutic Sales Value Share by Type (2021-2032) Figure 14. Lymphoma Image Figure 15. Thyroid Image Figure 16. Bone Metastasis Image Figure 17. Other Image Figure 18. Global Radiopharmaceuticals for Therapeutic Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Radiopharmaceuticals for Therapeutic Sales Value Share 2021 VS 2025 VS 2032 Figure 20. Global Radiopharmaceuticals for Therapeutic Sales Value Share by Application (2021-2032) Figure 21. Global Radiopharmaceuticals for Therapeutic Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 22. Global Radiopharmaceuticals for Therapeutic Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 23. North America Radiopharmaceuticals for Therapeutic Sales Value (2021-2032) & (US$ Million) Figure 24. North America Radiopharmaceuticals for Therapeutic Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Europe Radiopharmaceuticals for Therapeutic Sales Value (2021-2032) & (US$ Million) Figure 26. Europe Radiopharmaceuticals for Therapeutic Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Asia-Pacific Radiopharmaceuticals for Therapeutic Sales Value (2021-2032) & (US$ Million) Figure 28. Asia-Pacific Radiopharmaceuticals for Therapeutic Sales Value Share by Country (%), 2025 VS 2032 Figure 29. South America Radiopharmaceuticals for Therapeutic Sales Value (2021-2032) & (US$ Million) Figure 30. South America Radiopharmaceuticals for Therapeutic Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Middle East & Africa Radiopharmaceuticals for Therapeutic Sales Value (2021-2032) & (US$ Million) Figure 32. Middle East & Africa Radiopharmaceuticals for Therapeutic Sales Value Share by Country (%), 2025 VS 2032 Figure 33. USA Radiopharmaceuticals for Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. USA Radiopharmaceuticals for Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. USA Radiopharmaceuticals for Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Canada Radiopharmaceuticals for Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Canada Radiopharmaceuticals for Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Canada Radiopharmaceuticals for Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Mexico Radiopharmaceuticals for Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Mexico Radiopharmaceuticals for Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Mexico Radiopharmaceuticals for Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Germany Radiopharmaceuticals for Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Germany Radiopharmaceuticals for Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Germany Radiopharmaceuticals for Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. France Radiopharmaceuticals for Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. France Radiopharmaceuticals for Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. France Radiopharmaceuticals for Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. U.K. Radiopharmaceuticals for Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. U.K. Radiopharmaceuticals for Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. U.K. Radiopharmaceuticals for Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Italy Radiopharmaceuticals for Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Italy Radiopharmaceuticals for Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Italy Radiopharmaceuticals for Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Spain Radiopharmaceuticals for Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Spain Radiopharmaceuticals for Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Spain Radiopharmaceuticals for Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Russia Radiopharmaceuticals for Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Russia Radiopharmaceuticals for Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Russia Radiopharmaceuticals for Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Netherlands Radiopharmaceuticals for Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Netherlands Radiopharmaceuticals for Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Netherlands Radiopharmaceuticals for Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Nordic Countries Radiopharmaceuticals for Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Nordic Countries Radiopharmaceuticals for Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Nordic Countries Radiopharmaceuticals for Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. China Radiopharmaceuticals for Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. China Radiopharmaceuticals for Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. China Radiopharmaceuticals for Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Japan Radiopharmaceuticals for Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Japan Radiopharmaceuticals for Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Japan Radiopharmaceuticals for Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. South Korea Radiopharmaceuticals for Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. South Korea Radiopharmaceuticals for Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. South Korea Radiopharmaceuticals for Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. India Radiopharmaceuticals for Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. India Radiopharmaceuticals for Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. India Radiopharmaceuticals for Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Australia Radiopharmaceuticals for Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Australia Radiopharmaceuticals for Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Australia Radiopharmaceuticals for Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Southeast Asia Radiopharmaceuticals for Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Southeast Asia Radiopharmaceuticals for Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Southeast Asia Radiopharmaceuticals for Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Brazil Radiopharmaceuticals for Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Brazil Radiopharmaceuticals for Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Brazil Radiopharmaceuticals for Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Argentina Radiopharmaceuticals for Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Argentina Radiopharmaceuticals for Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Argentina Radiopharmaceuticals for Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Chile Radiopharmaceuticals for Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Chile Radiopharmaceuticals for Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Chile Radiopharmaceuticals for Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Colombia Radiopharmaceuticals for Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Colombia Radiopharmaceuticals for Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Colombia Radiopharmaceuticals for Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Peru Radiopharmaceuticals for Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Peru Radiopharmaceuticals for Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Peru Radiopharmaceuticals for Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Radiopharmaceuticals for Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Saudi Arabia Radiopharmaceuticals for Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Saudi Arabia Radiopharmaceuticals for Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Israel Radiopharmaceuticals for Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Israel Radiopharmaceuticals for Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Israel Radiopharmaceuticals for Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. UAE Radiopharmaceuticals for Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. UAE Radiopharmaceuticals for Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. UAE Radiopharmaceuticals for Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Turkey Radiopharmaceuticals for Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Turkey Radiopharmaceuticals for Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Turkey Radiopharmaceuticals for Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Iran Radiopharmaceuticals for Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Iran Radiopharmaceuticals for Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Iran Radiopharmaceuticals for Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Egypt Radiopharmaceuticals for Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Egypt Radiopharmaceuticals for Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Egypt Radiopharmaceuticals for Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Years Considered Figure 118. Research Process Figure 119. Key Executives Interviewed

Scope & coverage.

Types
  • Radium-223
  • Lutetium-177
  • Iodine-131
  • Other
Applications
  • Lymphoma
  • Thyroid
  • Bone Metastasis
  • Other
Companies covered
  • Novartis
  • Bayer
  • Q BioMed
  • Mundipharma
  • Lantheus
  • Jubilant Radiopharma
  • International Isotopes
  • Dongcheng
  • Curium Pharmaceuticals
  • China Isotope & Radiation
  • Aurobindo Pharma

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Radiopharmaceuticals for Therapeutic Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Radiopharmaceuticals for Therapeutic Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Radiopharmaceuticals for Therapeutic Market Dynamics
  1. 2.1 Radiopharmaceuticals for Therapeutic Industry Trends
  2. 2.2 Radiopharmaceuticals for Therapeutic Industry Drivers
  3. 2.3 Radiopharmaceuticals for Therapeutic Industry Opportunities and Challenges
  4. 2.4 Radiopharmaceuticals for Therapeutic Industry Restraints
3 Radiopharmaceuticals for Therapeutic Market by Company
  1. 3.1 Global Radiopharmaceuticals for Therapeutic Company Revenue Ranking in 2025
  2. 3.2 Global Radiopharmaceuticals for Therapeutic Revenue by Company (2021-2026)
  3. 3.3 Global Radiopharmaceuticals for Therapeutic Company Ranking (2024-2026)
  4. 3.4 Global Radiopharmaceuticals for Therapeutic Company Manufacturing Base and Headquarters
  5. 3.5 Global Radiopharmaceuticals for Therapeutic Company Product Type and Application
  6. 3.6 Global Radiopharmaceuticals for Therapeutic Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Radiopharmaceuticals for Therapeutic Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Radiopharmaceuticals for Therapeutic Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Radiopharmaceuticals for Therapeutic Market by Type
  1. 4.1 Radiopharmaceuticals for Therapeutic Type Introduction
  2. 4.1.1 Radium-223
  3. 4.1.2 Lutetium-177
  4. 4.1.3 Iodine-131
  5. 4.1.4 Other
  6. 4.2 Global Radiopharmaceuticals for Therapeutic Sales Value by Type
  7. 4.2.1 Global Radiopharmaceuticals for Therapeutic Sales Value by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Radiopharmaceuticals for Therapeutic Sales Value by Type (2021-2032)
  9. 4.2.3 Global Radiopharmaceuticals for Therapeutic Sales Value Share by Type (2021-2032)
5 Radiopharmaceuticals for Therapeutic Market by Application
  1. 5.1 Radiopharmaceuticals for Therapeutic Application Introduction
  2. 5.1.1 Lymphoma
  3. 5.1.2 Thyroid
  4. 5.1.3 Bone Metastasis
  5. 5.1.4 Other
  6. 5.2 Global Radiopharmaceuticals for Therapeutic Sales Value by Application
  7. 5.2.1 Global Radiopharmaceuticals for Therapeutic Sales Value by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Radiopharmaceuticals for Therapeutic Sales Value by Application (2021-2032)
  9. 5.2.3 Global Radiopharmaceuticals for Therapeutic Sales Value Share by Application (2021-2032)
6 Radiopharmaceuticals for Therapeutic Regional Value Analysis
  1. 6.1 Global Radiopharmaceuticals for Therapeutic Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Radiopharmaceuticals for Therapeutic Sales Value by Region (2021-2032)
  3. 6.2.1 Global Radiopharmaceuticals for Therapeutic Sales Value by Region: 2021-2026
  4. 6.2.2 Global Radiopharmaceuticals for Therapeutic Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Radiopharmaceuticals for Therapeutic Sales Value (2021-2032)
  7. 6.3.2 North America Radiopharmaceuticals for Therapeutic Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Radiopharmaceuticals for Therapeutic Sales Value (2021-2032)
  10. 6.4.2 Europe Radiopharmaceuticals for Therapeutic Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Radiopharmaceuticals for Therapeutic Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Radiopharmaceuticals for Therapeutic Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Radiopharmaceuticals for Therapeutic Sales Value (2021-2032)
  16. 6.6.2 South America Radiopharmaceuticals for Therapeutic Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Radiopharmaceuticals for Therapeutic Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Radiopharmaceuticals for Therapeutic Sales Value Share by Country, 2025 VS 2032
7 Radiopharmaceuticals for Therapeutic Country-level Value Analysis
  1. 7.1 Global Radiopharmaceuticals for Therapeutic Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Radiopharmaceuticals for Therapeutic Sales Value by Country (2021-2032)
  3. 7.2.1 Global Radiopharmaceuticals for Therapeutic Sales Value by Country (2021-2026)
  4. 7.2.2 Global Radiopharmaceuticals for Therapeutic Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Radiopharmaceuticals for Therapeutic Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Radiopharmaceuticals for Therapeutic Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Radiopharmaceuticals for Therapeutic Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Radiopharmaceuticals for Therapeutic Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Radiopharmaceuticals for Therapeutic Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Radiopharmaceuticals for Therapeutic Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Radiopharmaceuticals for Therapeutic Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Radiopharmaceuticals for Therapeutic Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Radiopharmaceuticals for Therapeutic Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Radiopharmaceuticals for Therapeutic Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Radiopharmaceuticals for Therapeutic Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Radiopharmaceuticals for Therapeutic Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Radiopharmaceuticals for Therapeutic Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Radiopharmaceuticals for Therapeutic Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Radiopharmaceuticals for Therapeutic Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Radiopharmaceuticals for Therapeutic Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Radiopharmaceuticals for Therapeutic Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Radiopharmaceuticals for Therapeutic Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Radiopharmaceuticals for Therapeutic Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Radiopharmaceuticals for Therapeutic Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Radiopharmaceuticals for Therapeutic Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Radiopharmaceuticals for Therapeutic Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Radiopharmaceuticals for Therapeutic Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Radiopharmaceuticals for Therapeutic Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Radiopharmaceuticals for Therapeutic Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Radiopharmaceuticals for Therapeutic Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Radiopharmaceuticals for Therapeutic Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Radiopharmaceuticals for Therapeutic Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Radiopharmaceuticals for Therapeutic Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Radiopharmaceuticals for Therapeutic Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Radiopharmaceuticals for Therapeutic Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Radiopharmaceuticals for Therapeutic Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Radiopharmaceuticals for Therapeutic Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Radiopharmaceuticals for Therapeutic Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Radiopharmaceuticals for Therapeutic Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Radiopharmaceuticals for Therapeutic Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Radiopharmaceuticals for Therapeutic Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Radiopharmaceuticals for Therapeutic Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Radiopharmaceuticals for Therapeutic Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Radiopharmaceuticals for Therapeutic Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Radiopharmaceuticals for Therapeutic Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Radiopharmaceuticals for Therapeutic Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Radiopharmaceuticals for Therapeutic Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Radiopharmaceuticals for Therapeutic Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Radiopharmaceuticals for Therapeutic Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Radiopharmaceuticals for Therapeutic Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Radiopharmaceuticals for Therapeutic Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Radiopharmaceuticals for Therapeutic Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Radiopharmaceuticals for Therapeutic Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Radiopharmaceuticals for Therapeutic Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Radiopharmaceuticals for Therapeutic Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Radiopharmaceuticals for Therapeutic Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Radiopharmaceuticals for Therapeutic Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Radiopharmaceuticals for Therapeutic Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Radiopharmaceuticals for Therapeutic Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Radiopharmaceuticals for Therapeutic Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Radiopharmaceuticals for Therapeutic Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Radiopharmaceuticals for Therapeutic Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Radiopharmaceuticals for Therapeutic Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Radiopharmaceuticals for Therapeutic Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Radiopharmaceuticals for Therapeutic Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Radiopharmaceuticals for Therapeutic Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Radiopharmaceuticals for Therapeutic Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Radiopharmaceuticals for Therapeutic Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Radiopharmaceuticals for Therapeutic Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Radiopharmaceuticals for Therapeutic Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Radiopharmaceuticals for Therapeutic Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Radiopharmaceuticals for Therapeutic Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Radiopharmaceuticals for Therapeutic Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Radiopharmaceuticals for Therapeutic Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Radiopharmaceuticals for Therapeutic Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Radiopharmaceuticals for Therapeutic Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Radiopharmaceuticals for Therapeutic Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Radiopharmaceuticals for Therapeutic Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Radiopharmaceuticals for Therapeutic Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Radiopharmaceuticals for Therapeutic Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Radiopharmaceuticals for Therapeutic Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Radiopharmaceuticals for Therapeutic Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Radiopharmaceuticals for Therapeutic Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Radiopharmaceuticals for Therapeutic Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Radiopharmaceuticals for Therapeutic Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Radiopharmaceuticals for Therapeutic Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Radiopharmaceuticals for Therapeutic Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Radiopharmaceuticals for Therapeutic Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Novartis
  2. 8.1.1 Novartis Company Information
  3. 8.1.2 Novartis Business Overview
  4. 8.1.3 Novartis Radiopharmaceuticals for Therapeutic Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Novartis Radiopharmaceuticals for Therapeutic Product Portfolio
  6. 8.1.5 Novartis Recent Developments
  7. 8.2 Bayer
  8. 8.2.1 Bayer Company Information
  9. 8.2.2 Bayer Business Overview
  10. 8.2.3 Bayer Radiopharmaceuticals for Therapeutic Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Bayer Radiopharmaceuticals for Therapeutic Product Portfolio
  12. 8.2.5 Bayer Recent Developments
  13. 8.3 Q BioMed
  14. 8.3.1 Q BioMed Company Information
  15. 8.3.2 Q BioMed Business Overview
  16. 8.3.3 Q BioMed Radiopharmaceuticals for Therapeutic Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Q BioMed Radiopharmaceuticals for Therapeutic Product Portfolio
  18. 8.3.5 Q BioMed Recent Developments
  19. 8.4 Mundipharma
  20. 8.4.1 Mundipharma Company Information
  21. 8.4.2 Mundipharma Business Overview
  22. 8.4.3 Mundipharma Radiopharmaceuticals for Therapeutic Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Mundipharma Radiopharmaceuticals for Therapeutic Product Portfolio
  24. 8.4.5 Mundipharma Recent Developments
  25. 8.5 Lantheus
  26. 8.5.1 Lantheus Company Information
  27. 8.5.2 Lantheus Business Overview
  28. 8.5.3 Lantheus Radiopharmaceuticals for Therapeutic Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Lantheus Radiopharmaceuticals for Therapeutic Product Portfolio
  30. 8.5.5 Lantheus Recent Developments
  31. 8.6 Jubilant Radiopharma
  32. 8.6.1 Jubilant Radiopharma Company Information
  33. 8.6.2 Jubilant Radiopharma Business Overview
  34. 8.6.3 Jubilant Radiopharma Radiopharmaceuticals for Therapeutic Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Jubilant Radiopharma Radiopharmaceuticals for Therapeutic Product Portfolio
  36. 8.6.5 Jubilant Radiopharma Recent Developments
  37. 8.7 International Isotopes
  38. 8.7.1 International Isotopes Company Information
  39. 8.7.2 International Isotopes Business Overview
  40. 8.7.3 International Isotopes Radiopharmaceuticals for Therapeutic Revenue and Gross Margin (2021-2026)
  41. 8.7.4 International Isotopes Radiopharmaceuticals for Therapeutic Product Portfolio
  42. 8.7.5 International Isotopes Recent Developments
  43. 8.8 Dongcheng
  44. 8.8.1 Dongcheng Company Information
  45. 8.8.2 Dongcheng Business Overview
  46. 8.8.3 Dongcheng Radiopharmaceuticals for Therapeutic Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Dongcheng Radiopharmaceuticals for Therapeutic Product Portfolio
  48. 8.8.5 Dongcheng Recent Developments
  49. 8.9 Curium Pharmaceuticals
  50. 8.9.1 Curium Pharmaceuticals Company Information
  51. 8.9.2 Curium Pharmaceuticals Business Overview
  52. 8.9.3 Curium Pharmaceuticals Radiopharmaceuticals for Therapeutic Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Curium Pharmaceuticals Radiopharmaceuticals for Therapeutic Product Portfolio
  54. 8.9.5 Curium Pharmaceuticals Recent Developments
  55. 8.10 China Isotope & Radiation
  56. 8.10.1 China Isotope & Radiation Company Information
  57. 8.10.2 China Isotope & Radiation Business Overview
  58. 8.10.3 China Isotope & Radiation Radiopharmaceuticals for Therapeutic Revenue and Gross Margin (2021-2026)
  59. 8.10.4 China Isotope & Radiation Radiopharmaceuticals for Therapeutic Product Portfolio
  60. 8.10.5 China Isotope & Radiation Recent Developments
  61. 8.11 Aurobindo Pharma
  62. 8.11.1 Aurobindo Pharma Company Information
  63. 8.11.2 Aurobindo Pharma Business Overview
  64. 8.11.3 Aurobindo Pharma Radiopharmaceuticals for Therapeutic Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Aurobindo Pharma Radiopharmaceuticals for Therapeutic Product Portfolio
  66. 8.11.5 Aurobindo Pharma Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst